I am pleased to announce that a BiotechDueDiligence stock research page for Retrophin $RTRX - the newly public biotech company headed by Martin Shkreli - is live.
Retrophin's lead drug, RE-021 for FSGS, is licensed from Ligand Pharma LGND (a long-time BDD favorite) and Bristol Myers Squibb BMY. The drug candidate is a vestige of a Pharmacopeia PCOP - Schering Plough SGP drug discovery alliance.
The Retrophin page features a complete slide deck from the company's recent presentation at the 2013 BIO CEO conference, along with extensive notes that I took while listening to the webcast. It all adds up to a great introduction to this new biotech player in the orphan disease arena.
RTRX also now has an entry on the Biotech Cash and Valuation page, where you'll find info on shares outstanding, net cash balance, and real-time valuation metrics for dozens of biotech stocks.
Retrophin's lead drug, RE-021 for FSGS, is licensed from Ligand Pharma LGND (a long-time BDD favorite) and Bristol Myers Squibb BMY. The drug candidate is a vestige of a Pharmacopeia PCOP - Schering Plough SGP drug discovery alliance.
The Retrophin page features a complete slide deck from the company's recent presentation at the 2013 BIO CEO conference, along with extensive notes that I took while listening to the webcast. It all adds up to a great introduction to this new biotech player in the orphan disease arena.
RTRX also now has an entry on the Biotech Cash and Valuation page, where you'll find info on shares outstanding, net cash balance, and real-time valuation metrics for dozens of biotech stocks.
RSS Feed
